Program
enlicitide chloride
Also written as “Enlicitide”, “Enlicitide Chloride” and “enlicitide”.
Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Renal Insufficiency · Hepatic Insufficiency, led by Merck.
Drug pageEnlicitide chloride: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 182 open or running | phase 3since Jun 4, 2024 | Oct 1, 2021 | Dec 14, 2026phase 1 · NCT07776665 |
Also a collaborator on its studies: Celerion.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Oct 1, 2021.
- Jan 19, 2023Named enlicitide chlorideINNProposed as its International Nonproprietary Name in WHO's List 128
- Jun 4, 2024Phase 3 study in HypercholesterolemiaNCT06450366 · 301 enrolled · United States, Argentina, Canada and more
- Aug 26, 2024Phase 1 study in Hepatic InsufficiencyNCT06575959 · 20 enrolled · United States
- Sep 12, 20242 phase 1 studies in HealthyNCT06597760, NCT06609512
- Oct 14, 20243 phase 1 studiesNCT06643377, NCT06655311, NCT06658626
- Dec 2, 2024Phase 1 study in HealthyNCT06719544 · 16 enrolled · United States
- Feb 3, 2025Phase 1 study in HealthyNCT06814106 · 37 enrolled · China
- Mar 12, 2025Phase 1 study in HealthyNCT06880874 · 40 enrolled · United States
- Jun 26, 2025Phase 1 study in HealthyNCT07044479 · 60 enrolled · United States
- Oct 10, 2025Phase 3 study in HyperlipidemiasNCT07216482 · 996 enrolled · United States, Argentina, Australia and more
- Dec 10, 2025Phase 1 study in HealthyNCT07300280 · 60 enrolled · United States
- Mar 16, 2026Phase 1 study in HealthyNCT07481708 · 30 enrolled · United States
- May 22, 2026Phase 2 study in Lipoprotein(a)NCT07614984 · 750 planned · United States, Canada, Colombia and more
- May 27, 2026Phase 1 study in HealthyNCT07619443 · 30 enrolled · United States
- Aug 17, 2026Phase 1 study in HealthyNCT07776665 · 30 enrolled · United States
Ahead
- Dec 14, 2026Primary completion: phase 1 study in HealthyNCT07776665
- Oct 12, 2027Primary completion: phase 2 study in Lipoprotein(a)NCT07614984
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07776665Healthy · United States | 1 | Active, not recruiting | Dec 14, 2026 | 30 |
| NCT07619443Healthy · United States | 1 | Completed | Sep 5, 2026 | 30 |
| NCT07614984Lipoprotein(a) · United States, Canada, Colombia and more | 2 | Recruiting | Oct 12, 2027 | 750 |
| NCT07481708Healthy · United States | 1 | Completed | May 18, 2026 | 30 |
| NCT07300280Healthy · United States | 1 | Completed | Oct 14, 2026 | 60 |
| NCT07216482Hyperlipidemias · United States, Argentina, Australia and more | 3 | Completed | Aug 3, 2026 | 996 |
| NCT07044479Healthy · United States | 1 | Completed | Aug 13, 2025 | 60 |
| NCT06880874Healthy · United States | 1 | Completed | May 16, 2025 | 40 |
| NCT06814106Healthy · China | 1 | Completed | May 8, 2023 | 37 |
| NCT06719544Healthy · United States | 1 | Completed | Jan 27, 2025 | 16 |
| NCT06658626Healthy · United States | 1 | Completed | Aug 2, 2023 | 8 |
| NCT06655311Hypercholesterolemia · United States | 1 | Completed | Jan 2, 2024 | 56 |
| NCT06643377Renal Insufficiency · United States | 1 | Completed | Jun 25, 2025 | 27 |
| NCT06609512Healthy · United States | 1 | Completed | Jan 13, 2025 | 20 |
| NCT06597760Healthy · United States | 1 | Completed | Nov 1, 2024 | 24 |
| NCT06575959Hepatic Insufficiency · United States | 1 | Completed | May 1, 2025 | 20 |
| NCT06450366Hypercholesterolemia · United States, Argentina, Canada and more | 3 | Completed | Feb 14, 2025 | 301 |
| NCT05070390Moderate Renal Impairment · United States | 1 | Completed | May 3, 2023 | 18 |
How it is read
Names in the registry
- “Enlicitide”, 13 entries
- “Enlicitide Chloride”, 3 entries
- “enlicitide”, 1 entry
- “[¹⁴C]Enlicitide chloride”, 1 entry
Conditions, from the studies’ own filings
- Hypercholesterolemia, 2 studies
- Hyperlipidemias, 1 study
- Renal Insufficiency, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.